CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

被引:13
作者
Le, Xiuning
Garassino, Marina Chiara
Cornelissen, Robin
Socinski, Mark A.
Tchekmedyian, Nishan
Molina, Julian R.
Baik, Christina S.
Leu, Sharon
Dreiling, Lyndah
Lebel, Francois M.
Clarke, Jeffrey Melson
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] IRCCS, Natl Canc Inst, Dept Med Oncol, Milan, Italy
[3] Erasmus MC, Rotterdam, Netherlands
[4] Advent Hlth Hematol & Oncol, Orlando, FL USA
[5] Pacif Shores Med Grp, Huntington Beach, CA USA
[6] Mayo Clin, Rochester, MN USA
[7] Seattle Canc Care Alliance, Seattle, WA USA
[8] Spectrum Pharmaceut, Irvine, CA USA
[9] Duke Univ, Med Ctr, Durham, NC USA
关键词
D O I
10.1200/JCO.2021.39.15_suppl.9093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
9093
引用
收藏
页数:2
相关论文
共 50 条
[21]   Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity [J].
Elamin, Yasir Y. ;
Robichaux, Jacqulyne P. ;
Carter, Brett W. ;
Altan, Mehmet ;
Tran, Hai ;
Gibbons, Don L. ;
Heeke, Simon ;
Fossella, Frank, V ;
Lam, Vincent K. ;
Le, Xiuning ;
Negrao, Marcelo, V ;
Nilsson, Monique B. ;
Patel, Anisha ;
Vijayan, R. S. K. ;
Cross, Jason B. ;
Zhang, Jianjun ;
Byers, Lauren A. ;
Lu, Charles ;
Cascone, Tina ;
Feng, Lei ;
Luthra, Rajyalakshmi ;
San Lucas, Francis A. ;
Mantha, Geeta ;
Routbort, Mark ;
Blumenschein, George, Jr. ;
Tsao, Anne S. ;
Heymach, John, V .
CANCER CELL, 2022, 40 (07) :754-+
[22]   Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. [J].
Yang, James Chih-Hsin ;
Wang, Mengzhao ;
Mitchell, Paul ;
Fang, Jian ;
Nian, Weiqi ;
Chiu, Chao-Hua ;
Zhou, Jianying ;
Zhao, Yanqiu ;
Su, Wu-Chou ;
Camidge, D. Ross ;
Yang, Tsung-Ying ;
Zhu, Viola Weijia ;
Millward, Michael ;
Fan, Yun ;
Huang, Wen Tsung ;
Cheng, Ying ;
Jiang, Liyan ;
Zheng, Li ;
Ye, Xiuhui ;
Janne, Pasi A. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23]   Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). [J].
Piotrowska, Zofia ;
Yu, Helena Alexandra ;
Yang, James Chih-Hsin ;
Koczywas, Marianna ;
Smit, Egbert F. ;
Tan, Daniel Shao-Weng ;
Lee, Victor Ho-Fun ;
Soo, Ross A. ;
Wrangle, John M. ;
Spira, Alexander I. ;
Velcheti, Vamsidhar ;
Socinski, Mark A. ;
Page, Asher ;
Witter, David ;
Zawel, Leigh ;
Wigginton, Jon M. ;
Clancy, Myles Steven ;
Nguyen, Danny .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24]   Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations [J].
Girard, N. ;
Bazhenova, L. ;
Minchom, A. ;
Ou, S. ;
Gadgeel, S. ;
Trigo, J. ;
Viteri, S. ;
Li, G. ;
Mahadevia, P. ;
Londhe, A. ;
Backenroth, D. ;
Li, T. ;
Bauml, J. M. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S145-S146
[25]   Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations [J].
Ou, Sai-Hong Ignatius ;
Lin, Huamao M. ;
Hong, Jin-Liern ;
Yin, Yu ;
Jin, Shu ;
Lin, Jianchang ;
Mehta, Minal ;
Nguyen, Danny ;
Neal, Joel W. .
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10)
[26]   Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment [J].
Yang, J. C. -H. ;
Wang, M. ;
Mitchell, P. ;
Fang, J. ;
Nian, W. ;
Chiu, C-H. ;
Zhou, J. ;
Zhao, Y. ;
Su, W. -C. ;
Camidge, R. ;
Yang, T. -Y. ;
Zhu, V. ;
Millward, M. ;
Fan, Y. ;
Huang, W. -T. ;
Cheng, Y. ;
Jiang, L. ;
Brungs, D. ;
Bazhenova, L. B. ;
Lee, C. K. ;
Gao, B. ;
Zheng, L. ;
Janne, P. .
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S410-S411
[27]   EGFR EXON 20 INSERTION MUTATIONS IN NSCLC: FREQUENCY AND TREATMENT OUTCOMES WITH EGFR DIRECTED TKIS [J].
Ovcaricek, T. ;
Unk, M. ;
Kern, I. ;
Cufer, T. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) :S64-S64
[28]   A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC [J].
Choi, D. ;
Jung, H. A. ;
Park, S. ;
Sun, J-M. ;
Ahn, J. S. ;
Ahn, M-J. ;
Lee, S-H. .
ANNALS OF ONCOLOGY, 2023, 34 :S1696-S1696
[29]   Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations [J].
Bazhenova, Lyudmila ;
Minchom, Anna ;
Viteri, Santiago ;
Bauml, Joshua M. ;
Ou, Sai-Hong Ignatius ;
Gadgeel, Shirish M. ;
Manuel Trigo, Jose ;
Backenroth, Daniel ;
Li, Tracy ;
Londhe, Anil ;
Mahadevia, Parthiv ;
Girard, Nicolas .
LUNG CANCER, 2021, 162 :154-161
[30]   Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies [J].
Le, X. ;
Prelaj, A. ;
Baik, C. ;
Tchekmedyian, N. ;
Leu, S. ;
Bhat, G. ;
Heymach, J. V. ;
Cornelissen, R. .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S147-S148